Gregory A Daniels, MD, PhD
Professor of Medicine
Moores Cancer Center
UC San Diego Health
La Jolla, CA
This enduring activity is focused on the management of patients with advanced or metastatic cutaneous squamous cell
This activity is designed to meet the educational needs of surgical dermatologists, Mohs surgeons, surgical oncologists,
dermatologists, and other healthcare practitioners who care for patients with advanced or metastatic cutaneous squamous
On completing this program, attendees should be able to:
- Compare the relative effectiveness of tumor staging systems for the identification of patients with cutaneous
squamous cell carcinoma (cSCC) at high-risk of recurrence or metastasis
- Utilize tumor staging and risk evaluation to stratify candidates for Mohs micrographic surgery, standard
excision, or nonsurgical interventions and discuss the benefits and risks of each therapeutic option
- Evaluate guidelines for surgical and pharmacologic treatment of cSCC based on clinical trial data
- Identify patients with unresectable cSCC who would benefit from targeted systemic therapy
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this activity for a maximum of 0.25 AMA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the online podcast
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Credits: 0.25 ANCC Contact Hour.
CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.25 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Gregory A Daniels, MD, PhD discloses that he is on the speakers’ bureau for Sanofi and Regeneron Pharmaceuticals, Inc.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or
relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Melissa A Johnson, Sr. Program Manager of Med Learning Group, has nothing to disclose.
Marcello A. Morgan, MD, MPH, Medical Director of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to
the audience when discussing any unlabeled or investigational use of any commercial product or device not yet
approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both
FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this activity. To
receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the activity.
- You will receive your certificate after the web-based activity.
You will receive your certificate upon completion.
Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility
to use this information to enhance their professional development in an effort to improve patient outcomes.
Conclusions drawn by the participants should be derived from careful consideration of all available scientific
information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision
making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy
statement information at http://medlearninggroup.com/privacy-policy/
RELEASE DATE: August 7, 2020
EXPIRATION DATE: August 7, 2021
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning
Group prior to participating at [email protected]
Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any
rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use
without the express written permission of Med Learning Group is prohibited.